Johnson & Johnson's (J&J) sales in India dipped 3% to ₹5,828 crore in the year ended March 2018. The drugmaker's medical device sales in India were hit following the government's move to cap prices of devices like orthopaedic knee implants. However, J&J's after-tax profit for the period rose 18% to around ₹687 crore on other income, including foreign exchange gains.